Stocksigma LogoStocksigma Logo

Moody’s and S&P Assign Investment-Grade Ratings to Sun Pharma

On 8th Sep'26, Moody's and S&P Global assigned Baa1 and preliminary BBB+ long-term issuer ratings, respectively, to Sun Pharma, both with a Stable outlook

Moody’s and S&P Assign Investment-Grade Ratings to Sun Pharma

Sun Pharmaceutical Industries Ltd · Others (Uncategorized) · 09 Sept 2026, 2:08 am

Moody’s and S&P Assign Investment-Grade Ratings to Sun Pharma On 8th Sep'26, Moody's and S&P Global assigned Baa1 and preliminary BBB+ long-term issuer ratings, respectively, to Sun Pharma, both with a Stable outlook. The ratings incorporate Sun Pharma’s planned $11.75bn acquisition of Organon, expected to close by early 2027. S&P expects the deal to double revenue to ~INR 1.3tn (~$14bn) by FY28, while Moody's anticipates $350m in cost synergies. Post-acquisition leverage will temporarily spike to 1.8x–3.0x, but robust cash flow is projected to reduce net debt-to-EBITDA toward 1.5x within 18–24 months.

Original exchange filing (PDF)

More announcements from Sun Pharmaceutical Industries Ltd

All Sun Pharmaceutical Industries Ltd announcements